AlphaYou
Overview
Key stats
Fundamentals Sep 10- Open
- $25.86
- 52-wk high
- $53.65
- High
- $26.55
- 52-wk low
- $22.01
- Low
- $24.39
- Prev close
- $26.37
- Mkt cap
- $1.37B
- Volume
- 401.4K
- Fwd P/E
- 8.5x
- P/S
- 68.3x
- P/B
- 3.2x
- Profit margin
- +0.0%
- Op margin
- -728.0%
- ROE
- -37.3%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsSmart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Activist stakes, short interest & more
Earnings
Earnings landed in line with what analysts expected.
Earnings per share
-$0.76 expected
What the street expects next
EPS expected
-$0.87 to -$0.66
Revenue expected
11 analysts
Estimate drift
Change in 30 days
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $0 | $0 | $20.0M | $0 |
| Cost of what it sold | — | $499.0K | $444.0K | — |
| Gross profit | — | -$499.0K | $19.6M | — |
| What it spent | ||||
| Research and development | $25.2M | $27.6M | $33.7M | $34.9M |
| Sales and admin | $7.8M | $10.5M | $12.4M | $13.1M |
| Other operating costs | — | -$499.0K | — | — |
| Total operating expenses | $33.0M | $37.6M | $46.1M | $48.0M |
| What was left | ||||
| Operating profit | -$33.0M | -$38.1M | -$26.6M | -$48.0M |
| Interest on debt | — | — | $866.0K | $931.0K |
| Profit before tax | -$30.1M | -$34.6M | -$24.2M | -$44.7M |
| Net profit | -$30.1M | -$34.6M | -$24.2M | -$44.7M |
| EBITDA | -$29.5M | -$34.1M | -$22.9M | -$43.8M |
Technicals
Price structure
This stock is under pressure, and looks oversold after a sharp drop.
Trend
Under pressure
0 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage leans bearish
Tone of tracked coverage
Courtney Phillips Executes 11,000 Zero-Cost Options in Maze Therapeutics (NASDAQ: MAZE) on September 1, 2026
NeutralSep 4Maze Therapeutics CSBO Atul Dandekar Sells 6,434 Shares to Cover RSU Tax Withholding
NeutralSep 4Maze Therapeutics CEO Jason V Coloma Reports RSU Vesting and Trust Share Sales in Form 4 Filing
NeutralSep 4Maze Therapeutics Officer Courtney Phillips Reports RSU Vesting and Stock Settlement
NeutralSep 4Maze Therapeutics CSBO Dandekar divests $206,823 of common stock
Leans bearishSep 1Maze Therapeutics CSBO Dandekar divests $206,823 of common stock By Investing.com
Leans bearishSep 1Maze Therapeutics, Inc. (MAZE) Reports Q1 Loss, Beats Revenue Estimates
NeutralAug 30
Macro
11 macro signals shaping MAZE right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results